DAYTON, Ohio, Jan 11, 2012 (BUSINESS WIRE) -- Riverain Technologies announced today that it has received 510(k) clearance from the Food and Drug Administration (FDA) for its Temporal Comparison software. This software electronically compares current and prior chest X-ray images and can help identify nodules that may be early-stage lung cancer, when there are more treatment options.
The first-of-its-kind technology zeros in on differences between current and prior chest X-rays of the same patient, drawing attention to what may be an emerging or enlarging tumor. The software aligns and registers the two patient images to produce a difference image, which allows radiologists to pinpoint even subtle changes that show up more clearly than on a traditional X-ray. Temporal Comparison also has received approval for marketing in the European Union.
In a study of 422 pairs of chest X-rays, 15 radiologists were able to demonstrate an average 12.4 percent improvement in sensitivity for actionable solitary pulmonary nodules using Riverain's Temporal Comparison software as compared to results based on comparing the X-rays side by side, today's standard.
source: Riverain Technologies
No comments:
Post a Comment